ADMA— AI Stock Forecast & Price Targets
Published 7/1/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live ADMA price forecast →
ADMA Biologics faces significant headwinds from a pending securities lawsuit and recent price volatility, but its strong fundamentals (high ROE, positive cash flow) and pipeline products offer long-term upside. The technicals analysis shows a downtrend from $20.45 to current price of $8.37, with resistance at $13.55 and support at $8.38. The Kronos AI forecast suggests continued downward pressure.
Wait for earnings (Aug 5) to validate the lawsuit impact; if price breaks below $8.38 support, consider shorting with stop-loss at $9.00. Invalidation: close above $13.55 resistance.
Hold through Q3 as pipeline products gain traction; target $17.75 by end of 2026 if lawsuit resolves favorably. Catalysts include FDA approvals for new products and improved margins from cost-cutting.
Long-term value lies in the plasma-derived therapeutics pipeline, with potential for 29.21% EPS growth over five years. Structural risk is regulatory scrutiny from the securities lawsuit, which could delay product launches or trigger further legal costs.
Revenue grew 10.99% YoY (Q2 2026), but margins are pressured by high debt-to-equity (110.67x) and negative operating margin (-1.23%). Strong cash flow ($58.3M Q2 2026) and ROE of 43.3% indicate operational efficiency, though the $9.7B debt is a major concern. The pipeline shows promise with products for S. pneumonia infection, but the securities lawsuit (June 2026) introduces regulatory risk.
The chart reveals a downtrend from $20.45 to current price of $8.37, with resistance at $13.55 and support at $8.38. The Kronos AI forecast band shows a bearish trajectory below the actual price line, indicating continued downward pressure. RSI (45.55) suggests neutral momentum but near-term weakness due to recent declines (-3.68% weekly).
The securities lawsuit alleging revenue inflation (June 2026) is a critical risk, though analyst sentiment remains bullish with a target of $17.75. Recent price action shows volatility: -4.34% on June 29 and +1.4% on June 23, reflecting market uncertainty. The pipeline's potential for S. pneumonia products offers growth but is overshadowed by legal risks.
- Pipeline products targeting S. pneumonia infection (mentioned in June 2026 news) offer high-growth potential with market expansion opportunities
- Securities lawsuit alleging revenue inflation (June 2026), which could lead to regulatory penalties and reduced investor confidence
- High debt-to-equity ratio (110.67x) increasing financial risk during downturns
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord